Stem cell research for progressive MS.
We have patients with MS who do weekly ozone before they go to Panama for stem cell therapy. What if you can do both at the same time?
According the current research taking place in Germany, high dose or 10 pass MAH Major Autohemotherapy does stimulate stem cells. The findings will be published later this year. 10 pass MAH may be safer, more accessible and the most cost-effective therapy to stimulate stem cells. Patients have to raise 25,000 to 30,000 dollars for their treatment in Panama. I think the clinicians in Panama are doing great things, but patients here need a cost-effective treatment modality. So far, our patients with MS are in remission after doing high dose and 10 pass MAH with specialized medicines from Germany.
There is no question that stem cell therapy works for many people with different conditions. It's a shame that we have a hard time getting legitimate stem cell therapy here at therapeutic levels to reverse chronic conditions.
Autologous hematopoietic stem cell transplantation (AHSCT) was associated with long-term attenuation of disability progression in almost half of patients with aggressive, treatment-refractory multiple sclerosis (MS), researchers found.
In a long-term observation published in JAMA neurology of 281 patients with predominantly progressive forms of MS found that 46% of the 239 evaluable patients were free from progression and overall survival was 93% at 5 years.
The researchers stated that the profile of a patient who may benefit from the AHSCT for treatment of aggressive MS includes being younger in age with relapsing forms of MS, a low number of prior immunotherapies and low or moderate, but not severe level of established neurological disability.
The results suggest a long-term treatment effect of AHSCT and strengthen the case for randomized trials of AHSCT against standard care.
Patients who participated in the study were followed for up to 16 years. Three-quarters of the patients had progressive forms of MS, mostly secondary. Transplant occurred at a median of 81 months after MS diagnosis and 61% of the patients had received at least 2 MS treatments prior to the transplant. Progression was more likely in patients who were older, had progressive vs. relapsing and had not responded to more than 2 previous disease-modifying therapies.
Recent years have seen increased utilization of low-intensity conditioning regimens, which are expected to be safer and better tolerated, but the question remains as to whether they are as effective as more intensive regimens.
The leading researcher also noted that patients selected for stem cell transplantation "should have MRI evidence of active inflammatory MS disease, which in the months preceding AHSCT, has been linked with better outcomes, and low or moderate ambulatory levels of neurological disability since patients in our study who were wheelchair-bound [at transplant] were significantly more likely to die during the post-transplant follow-up than patients with lower levels of disability."
The study was undertaken through collaboration with the Center for International Blood and Marrow Transplant Research (CIBMTR) Autoimmune Disease Working Committee and the European Blood and Marrow Transplant (EBMT) Group Autoimmune Disease Working Party. It involved patients who received AHSCT between January 1995 and December 2006 at 25 centers in 13 countries.
Reference:
JAMA Neurology
Call us and let's discuss your treatment options.
/blog/how-much-do-you-know-about-ms
/blog/ms-drug-and-increased-cancer-risk
